Sarcomas are rare cancers, accounting for less than 1% of all adult malignancies, yet they carry a disproportionate burden among children and adolescents. Bone and soft tissue sarcomas in adolescents and young adults are often misdiagnosed and require highly coordinated multimodal treatment. They demand specialist pathology, precise staging, and protocol-based systemic therapy to achieve durable outcomes. Historically, survival rates for patients with metastatic or recurrent disease have remained substantially lower than those seen in localized disease. This highlights the importance of timely diagnosis and specialized multidisciplinary care.
Case of an 18-Year-Old from Nairobi
Shayla (name changed), an 18-year-old from Nairobi, Kenya, arrived in Navi Mumbai with a recurrent swelling in the distal third of her left forearm. In 2021, she had undergone excision of a soft tissue mass at the same site in Kenya. Histopathology at that time had indicated monomorphic synovial sarcoma, but no adjuvant therapy had followed.
When the swelling returned, the clinical picture warranted a thorough reevaluation. MRI revealed a 2.3 × 1.9 × 7.6 cm heterogeneously enhancing solid cystic lesion on the dorsal aspect of the forearm. PET-CT confirmed metabolically active disease confined to the forearm, with no distant spread. The localized extent offered a window for definitive intervention, if the diagnosis could be nailed down.
Precision Pathology Changes the Course
Wide local excision and soft tissue reconstruction were performed by the orthopedic oncology team. The specimen was subjected to detailed histopathology and immunohistochemistry, which revealed undifferentiated small round cell sarcoma favoring Ewing sarcoma — a materially different diagnosis from what had been recorded three years earlier. Why was this distinction important? Ewing sarcoma carries its own biological behavior, chemosensitivity profile, and treatment protocol. In this case, the earlier misclassification, and the absence of adjuvant therapy that followed, had likely contributed to the recurrence.
Protocol-Based Treatment, Fully Delivered
Following multidisciplinary review, Shayla was started on adjuvant interval-compressed VAC/IE chemotherapy - vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide as per the EFT-2001 protocol. All chemotherapy cycles were completed as planned. Local radiotherapy was administered as consolidation. Fertility preservation counseling was offered prior to initiating treatment; the family declined.
Dr. Jyoti Bajpai, Lead Consultant, Medical and Precision Oncology, Apollo Hospitals Navi Mumbai said: "Shayla's journey is a powerful reminder of why expertise matters. Her initial diagnosis and treatment elsewhere did not fully capture the biological nature of her disease. When she presented to us with recurrence, a detailed pathological and molecular review revealed a different diagnosis that fundamentally changed her treatment plan. With coordinated multidisciplinary care, protocol-based chemotherapy, surgery, and radiotherapy, we were able to treat her with curative intent. Sarcomas are rare cancers, but rarity should never become a barrier to the right treatment. Every patient deserves an accurate diagnosis, expert review, and access to a multidisciplinary team familiar with these complex tumors. The difference between a good outcome and a missed opportunity often lies in getting to the right center at the right time. At Apollo, our commitment is to combine world-class expertise, precision diagnostics, and compassionate care so that every patient has the best possible chance of cure and long-term survival. Globally, only a limited number of centers and specialists manage large volumes of sarcoma patients. Over the years, I have had the privilege of training and working at some of the finest national and international institutions dedicated to cancer care, where we collectively treated thousands of patients, including a substantial number with these rare tumors. That experience has reinforced a simple but important lesson: in sarcoma, the right diagnosis, the right team, and the right treatment strategy can make a profound difference."
